STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner(Shaare Zedek Medical Center), Axel Dignaß(Goethe University Frankfurt), Walter Reinisch(Medical University of Vienna), Jean‐Frédéric Colombel(Mount Sinai Hospital), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Iris Dotan(Tel Aviv University), William J. Sandborn(University of San Diego), Ferdinando D’Amico(Humanitas University), Ayanna Lewis(University of Miami), Jasbir Dhaliwal(Cincinnati Children's Hospital Medical Center), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), David T. Rubin(University of California System), Willem A. Bemelman(Vrije Universiteit Amsterdam), Anne M. Griffiths(University of Toronto), Dominik Bettenworth(University Hospital Münster), Jürgen Schölmerich(University of Hohenheim), Amanda Ricciuto(University of Toronto), Jean Yves Mary(Inserm), María T. Abreu(Icahn School of Medicine at Mount Sinai)
Cited by 2,645
Related Papers
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k